Kinetic estimates of the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein AI after treatment with atorvastatin, fenofibrate, and placebo
| . | Atorvastatin . | Fenofibrate . | Placebo . | Group differences (P) . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Atorvastatin vs. placebo . | Fenofibrate vs. placebo . | Atorvastatin vs. fenofibrate . | ||
| Pool size (mg) | ||||||||
| VLDLapoB | 251 ± 32 | 302 ± 46 | 408 ± 47 | −156 ± 28 (<0.001) | −106 ± 35 (<0.001) | −50 ± 24 (0.041) | ||
| IDL apoB | 181 ± 23 | 232 ± 18 | 294 ± 26 | −112 ± 18 (<0.001) | −62 ± 32 (0.006) | −50 ± 26 (0.021) | ||
| LDL apoB | 1306 ± 116 | 2222 ± 129 | 2452 ± 143 | −1145 ± 93 (<0.001) | −230 ± 123 (0.017) | −915 ± 122 (<0.001) | ||
| HDL apoAI | 4951 ± 311 | 5307 ± 398 | 5007 ± 346 | −57 ± 153 (0.629) | 300 ± 133 (0.017) | −357 ± 57 (0.006) | ||
| Fractional catabolic rate (pools/day) | ||||||||
| VLDL apoB | 5.69 ± 0.52 | 5.00 ± 0.49 | 3.77 ± 0.30 | 1.92 ± 0.34 (0.001) | 1.25 ± 0.31 (<0.001) | 0.69 ± 0.48 (0.032) | ||
| IDL apoB | 5.96 ± 1.25 | 3.84 ± 0.40 | 2.86 ± 0.21 | 3.10 ± 1.17 (0.002) | 0.98 ± 0.31 (0.007) | 2.12 ± 1.17 (0.079) | ||
| LDL apoB | 0.76 ± 0.11 | 0.44 ± 0.02 | 0.35 ± 0.02 | 0.41 ± 0.12 (<0.001) | 0.09 ± 0.02 (<0.001) | 0.33 ± 0.12 (0.011) | ||
| HDL ApoAI | 0.30 ± 0.01 | 0.33 ± 0.02 | 0.30 ± 0.01 | 0.00 ± 0.01 (1.000) | 0.03 ± 0.01 (0.016) | −0.03 ± 0.02 (0.016) | ||
| PR (mg · kg−1 · day−1) | ||||||||
| VLDL apoB | 13.4 ± 1.19 | 13.4 ± 1.09 | 14.8 ± 1.38 | −1.31 ± 0.79 (0.098) | −1.19 ± 1.22 (0.131) | −0.12 ± 0.84 (0.876) | ||
| IDL apoB | 9.21 ± 1.06 | 8.72 ± 0.75 | 8.32 ± 0.57 | 0.88 ± 1.00 (0.263) | 0.39 ± 0.77 (0.615) | 0.49 ± 1.14 (0.529) | ||
| LDL apoB | 9.78 ± 1.13 | 10.1 ± 0.70 | 8.78 ± 0.58 | 1.00 ± 0.97 (0.148) | 1.31 ± 0.47 (0.061) | −0.32 ± 1.01 (0.637) | ||
| HDL ApoAI | 15.4 ± 0.7 | 18.1 ± 1.6 | 15.5 ± 0.84 | −0.13 ± 0.36 (0.845) | 2.59 ± 0.99 (0.001) | −2.72 ± 1.08 (<0.001) | ||
| Direct synthesis (%) | ||||||||
| VLDL apoB | 83 ± 2 | 74 ± 4 | 80 ± 3 | 3.5 ± 3.1 (0.228) | −6.1 ± 4.7 (0.044) | 9.7 ± 3.0 (0.003) | ||
| IDL apoB | 13 ± 2 | 19 ± 2 | 18 ± 2 | −5.0 ± 2.9 (0.038) | 1.2 ± 3.4 (0.619) | −6.2 ± 2.3 (0.013) | ||
| LDL apoB | 4 ± 1 | 8 ± 3 | 3 ± 1 | 1.5 ± 1.8 (0.401) | 5.0 ± 2.8 (0.009) | −3.5 ± 2.0 (0.058) | ||
| Conversion rate (%) | ||||||||
| VLDL to IDL apoB | 56 ± 8 | 39 ± 7 | 36 ± 5 | 20 ± 7 (0.008) | 2.7 ± 10 (0.700) | 17 ± 9.1 (0.020) | ||
| IDL to LDL apoB | 97 ± 3 | 100 | 100 | 2.5 ± 2.5 (0.131) | 0 ± 0 (1.000) | −2.51 ± 2.51 (0.131) | ||
| . | Atorvastatin . | Fenofibrate . | Placebo . | Group differences (P) . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Atorvastatin vs. placebo . | Fenofibrate vs. placebo . | Atorvastatin vs. fenofibrate . | ||
| Pool size (mg) | ||||||||
| VLDLapoB | 251 ± 32 | 302 ± 46 | 408 ± 47 | −156 ± 28 (<0.001) | −106 ± 35 (<0.001) | −50 ± 24 (0.041) | ||
| IDL apoB | 181 ± 23 | 232 ± 18 | 294 ± 26 | −112 ± 18 (<0.001) | −62 ± 32 (0.006) | −50 ± 26 (0.021) | ||
| LDL apoB | 1306 ± 116 | 2222 ± 129 | 2452 ± 143 | −1145 ± 93 (<0.001) | −230 ± 123 (0.017) | −915 ± 122 (<0.001) | ||
| HDL apoAI | 4951 ± 311 | 5307 ± 398 | 5007 ± 346 | −57 ± 153 (0.629) | 300 ± 133 (0.017) | −357 ± 57 (0.006) | ||
| Fractional catabolic rate (pools/day) | ||||||||
| VLDL apoB | 5.69 ± 0.52 | 5.00 ± 0.49 | 3.77 ± 0.30 | 1.92 ± 0.34 (0.001) | 1.25 ± 0.31 (<0.001) | 0.69 ± 0.48 (0.032) | ||
| IDL apoB | 5.96 ± 1.25 | 3.84 ± 0.40 | 2.86 ± 0.21 | 3.10 ± 1.17 (0.002) | 0.98 ± 0.31 (0.007) | 2.12 ± 1.17 (0.079) | ||
| LDL apoB | 0.76 ± 0.11 | 0.44 ± 0.02 | 0.35 ± 0.02 | 0.41 ± 0.12 (<0.001) | 0.09 ± 0.02 (<0.001) | 0.33 ± 0.12 (0.011) | ||
| HDL ApoAI | 0.30 ± 0.01 | 0.33 ± 0.02 | 0.30 ± 0.01 | 0.00 ± 0.01 (1.000) | 0.03 ± 0.01 (0.016) | −0.03 ± 0.02 (0.016) | ||
| PR (mg · kg−1 · day−1) | ||||||||
| VLDL apoB | 13.4 ± 1.19 | 13.4 ± 1.09 | 14.8 ± 1.38 | −1.31 ± 0.79 (0.098) | −1.19 ± 1.22 (0.131) | −0.12 ± 0.84 (0.876) | ||
| IDL apoB | 9.21 ± 1.06 | 8.72 ± 0.75 | 8.32 ± 0.57 | 0.88 ± 1.00 (0.263) | 0.39 ± 0.77 (0.615) | 0.49 ± 1.14 (0.529) | ||
| LDL apoB | 9.78 ± 1.13 | 10.1 ± 0.70 | 8.78 ± 0.58 | 1.00 ± 0.97 (0.148) | 1.31 ± 0.47 (0.061) | −0.32 ± 1.01 (0.637) | ||
| HDL ApoAI | 15.4 ± 0.7 | 18.1 ± 1.6 | 15.5 ± 0.84 | −0.13 ± 0.36 (0.845) | 2.59 ± 0.99 (0.001) | −2.72 ± 1.08 (<0.001) | ||
| Direct synthesis (%) | ||||||||
| VLDL apoB | 83 ± 2 | 74 ± 4 | 80 ± 3 | 3.5 ± 3.1 (0.228) | −6.1 ± 4.7 (0.044) | 9.7 ± 3.0 (0.003) | ||
| IDL apoB | 13 ± 2 | 19 ± 2 | 18 ± 2 | −5.0 ± 2.9 (0.038) | 1.2 ± 3.4 (0.619) | −6.2 ± 2.3 (0.013) | ||
| LDL apoB | 4 ± 1 | 8 ± 3 | 3 ± 1 | 1.5 ± 1.8 (0.401) | 5.0 ± 2.8 (0.009) | −3.5 ± 2.0 (0.058) | ||
| Conversion rate (%) | ||||||||
| VLDL to IDL apoB | 56 ± 8 | 39 ± 7 | 36 ± 5 | 20 ± 7 (0.008) | 2.7 ± 10 (0.700) | 17 ± 9.1 (0.020) | ||
| IDL to LDL apoB | 97 ± 3 | 100 | 100 | 2.5 ± 2.5 (0.131) | 0 ± 0 (1.000) | −2.51 ± 2.51 (0.131) | ||
Data are means ± SEM.